Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,208 across all filing types
Latest filing 2024-01-29 Proxy Solicitation & In…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Letter to Shareholders - Notice of General Meeting 3 pages 190.4KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of General Meeting of Shareholders and a Proxy Form for Botanix Pharmaceuticals Limited. It includes details about the meeting date, location, proxy submission instructions, and voting procedures. There is no financial data, earnings information, or management discussion. The document is a formal invitation and voting instruction for shareholders to participate in the meeting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is over 10,000 characters, indicating it is a full proxy statement rather than a brief announcement. Therefore, the correct classification is PSI.
2024-01-29 English
NDA Resubmission Accepted and Approval Date Confirmed 3 pages 183.3KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 22 January 2024 regarding the resubmission and acceptance of a New Drug Application (NDA) by the FDA for a product called Sofdra. It details the FDA's acceptance of the resubmission as a complete response, the classification of the review period, and the target approval date. The document focuses on regulatory progress and commercial launch preparations rather than financial results or detailed financial data. It is a regulatory update about the status of a drug approval process rather than a financial report, earnings release, or management discussion. The document is relatively short (5625 characters) and serves as a formal announcement to investors and the market about the regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance documents that do not fit other specific categories.
2024-01-21 English
Application for quotation of securities - BOT 6 pages 28.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into fully paid ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a clear announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. There is no indication of it being a full financial report, earnings release, or management discussion. The document fits the category of announcements regarding new share issues or capital changes.
2024-01-14 English
Section 708A(5)(e) Notice 2 pages 147.0KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of new shares by Botanix Pharmaceuticals Limited. It provides legal and regulatory compliance information about the share issuance and the exemption from disclosure requirements. The document is short (2399 characters) and serves as a formal notification to the market rather than a detailed financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not an announcement of a report publication but a regulatory compliance notice related to capital changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-01-14 English
Application for quotation of securities - BOT 6 pages 28.0KB
Capital/Financing Update Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into fully paid ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update regarding securities issuance and quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-01-07 English
Section 708A(5)(e) Notice 2 pages 146.9KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of new shares on exercise of options. It provides legal and regulatory compliance information about the share issue and the exemption from disclosure requirements. The document is short (2398 characters) and serves as a formal notification to the market rather than a detailed financial report or announcement of financial results. It does not contain financial statements or detailed analysis, nor is it a report or presentation. It is a regulatory announcement about a capital transaction but does not detail the capital change itself (which would be a SHA filing). Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-07 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.